<?xml version="1.0" encoding="UTF-8"?>
<p> After 20 years’ effort, serologic incidence estimation has yet to achieve proof of concept. All survey results require extensive mathematical manipulation, and reinterpretations are frequent. All assay methods evaluated to date extensively misclassify persons on ART, which inflates incidence estimates.  CDC’s domestic surveillance has abandoned serologic incidence assays in favor of a CD4 depletion model (Hall 
 <italic>et al.</italic>, 2017 
 <sup>
  <xref rid="rep-ref-27584-11" ref-type="bibr">11</xref>
 </sup>).
</p>
